Founder BRCA1 and BRCA2 mutations in French Canadian ovarian cancer cases unselected for family history

Clinical Genetics

Volumn 55, Issue 5, 1999, Pages 318-324

  Tonin, Patricia N ^a   Mes Masson, Anne Marie ^b   Narod, Steven A ^c   Ghadirian, Parviz ^d   Provencher, Diane ^b  

^a MONTREAL GENERAL HOSPITAL   (Canada)

^b Institut du Cancer de Montreal   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

BRCA1; BRCA2; Breast cancer; Ovarian cancer

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

ARTICLE; CANADA; FAMILY HISTORY; FEMALE; GENE MUTATION; HUMAN; INVASIVE CARCINOMA; MAJOR CLINICAL STUDY; ONCOGENE; OVARY CANCER; PRIORITY JOURNAL;

EID: 0033028701     PISSN: 00099163     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-0004.1999.550504.x     Document Type: Article

References (42)

1. National Cancer Institute of Canada. Canadian Cancer Statistics, 1998, Toronto, Canada.
2. Lynch HT, Bewtra C, Lynch JF. Familial ovarian carcinoma. Am J Med 1986: 81: 1073-1076.
3. Miki Y, Swenson J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Lui Q, Cochran C, Bennett LM, Ding W. Bell R, Rosenthal J, Hussey C, Tran T, McClure M, Frye C, Hattier T, Phelps R, Haugen-Strano A, Katcher H, Yakumo K, Gholami Z, Shaffer D, Stone S, Bayer S, Wray C, Bogden R, Dayananth P, Ward J, Tonin P, Narod S, Bristow PK, Norris FH, Helvering L, Morrison P, Rosteck P, Lai M, Barrett JC, Lewis C, Neuhausen S, Cannon-Albright L, Goldgar D. Wiseman R, Kamb A, Skolnick MH. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994: 266: 66-71.
4. Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, Collins N, Gregory S, Gumbs C, Micklem G, Barfoot R, Hamoudi R, Patel S, Rice C, Biggs P, Hashim Y. Smith A, Connor F, Arason A, Gudmundsson J, Ficenec D, Kelsell D, Ford D. Tonin P, Bishop DT, Spurr NK, Ponder BAJ, Eeles R, Peto J, Devilee P, Cornelisse C, Lynch H, Narod S, LenoirG, Egilsson V, Barkadottir RB, Easton DF, Bentley DR, Futreal PA, Ashworth A, Stratton MR. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995: 378: 789-792.
5. Tavtigian SV, Simard J, Rommens J. Couch F, Shattuck-Eidens D, Neuhausen S, Merajaver S, Thorlacius S, Offit K, Stoppa-Lyonnet D, Belanger C, Bell R, Berry S. Bogden R, Chen Q, Davis T, Dumont M, Frye C, Hattier T, Jammulapati S, Janecki T, Jiang P, Kehrer R, Leblanc J-F, Mitchell JT, McArthur-Morrison J, Nguyen K, Peng Y, Samson C, Schroeder M, Snyder SC, Steele L, Stringfellow M, Stroup C, Swedlund B, Swenson J, Teng D, Thomas A, Tran T, Tran T, Tranchant M, Weaver-Feldhaus J, Wong AKC, Shizuya H, Eyfjord JE, Cannon-Albright L, Labrie F, Skolnick MH, Weber B, Kamb A, Goldgar DE. The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. Nat Genet 1996: 12: 333-337.
6. Breast Cancer Linkage Consortium, Narod SA, Ford D, Devilee P, Barkardottir RB, Lynch HT, Smith SA, Ponder BAJ, Weber BL, Garber JE, Birch JM, Cornelis RS, Kelsell DP, Spurr NK, Symth E. Haites N, Sobol H, Bignon Y-J, Chang-Claude J, Haman U, Lindblom A, Borg A, Piver MS, Gallion HH, Struewing JP, Whittemore A, Tonin P, Goldgar DE, Easton DF. An evaluation of genetic heterogeneity in 145 breast-ovarian cancer families. Am J Hum Genet 1995: 56: 254-264.
7. Tonin P, Weber B. Offit K, Couch F, Rebbeck TR, Neuhausen S, Godwin AK, Daly M, Wagner-Costalos J, Berman D, Grana G. Fox E, Kane MF, Kolodner RD, Krainer M, Haber DA, Struewing JP, Warner E, Rosen B, Lerman C, Peshkin B, Norton L, Serova O, Foulkes WD, Lynch HT, Lenoir GM, Narod SA, Garber JE. Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families. Nat Med 1996: 2: 1179-1183.
8. Serova O, Montana M, Torchard D. Narod SA, Tonin P, Sylla B, Lynch HT, Feunteun J, Lenoir GM. A high incidence of BRCA1 mutations in 20 breast-ovarian cancer families. Am J Hum Genet 1996: 58: 42-51.
9. The Breast Cancer Linkage Consortium, Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, Bishop DT, Weber B. Lenoir G, Chang-Claude J, Sobol H, Teare MD, Struewing J, Arason A, Scherneck S, Peto J, Rebbeck TR, Tonin P, Neuhausen S, Barkardottir R, Eyfjord J, Lynch H, Ponder BAJ, Gayther S, Birch SM, Lindblom A, Stoppa-Lyonnet D, Bignon Y, Borg A, Hamman L, Haites N, Scott RJ, Maugard CM, Vasen H, Seitz S, Cannon-Albright LA, Schofield A, Zelada-Hedman M. Genetic heterogeneity and penetrance analysis of BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet 1998: 62: 676-689.
10. Gayther SA, Mangion J, Russell P, Seal S, Barfoot R, Ponder BAJ, Stratton MR, Easton D. Variation of risks of breast and ovarian cancer associated with different germline mutations of BRCA2 gene. Nat Genet 1997: 15: 103-105.
11. Steichen-Gersdorf E, Gallion HH, Ford D, Girodet C, Easton DF. DiCoccio RA, Evans G, Ponder MA, Mazoyer S, Noguchi T, Karengueren F. Sobol H, Hardouin A, Bignon Y-J, Piver MA, Smith SA, Ponder BAJ. Familial site-specific ovarian cancer is linked to BRCA1 on 17q12-21. Am J Hum Genet 1994: 55: 870-875.
12. Gayther SA, Harrington P, Russell P. Kharkevich G. Garkavtseva RF, Ponder BAJ. Frequently occurring germline mutations of the BRCA1 gene in ovarian cancer families from Russia. Am J Hum Genet 1997: 60: 1239-1242.
13. Liede A, Tonin PN, Sun CC, Serruya C, Daly MB, Narod SA, Foulkes WD. Is hereditary site-specific ovarian cancer a distinct condition? Am J Med Genet 1998: 75: 55-58.
14. Vasen HFA, Den Hartog Jager FCA, Menko FH. Screening for hereditary non-polyposis colorectal cancer: a study of 22 kindreds in The Netherlands. Am J Med 1989: 86: 278-281.
15. Watson P, Lynch HT. Extracolonic cancer in hereditary nonpolyposis colorectal cancer. Cancer 1993: 71: 677-685.
16. Nyström-Lahti M, Parsons R, Sistonen P, Pylkänen L. Aatonen LA, Leach FS, Hamilton SR, Watson P, Bronson E, Fusaro R. Cavelieri J, Lynch J. Lanspa S. Smyrk T, Lynch P, Drouhard T, Kinzler KW, Vogelstein B, Lynch HT, de la Chapelle A, Peltomäki P. Mismatch repair genes on chromosome 2p and 3p account for a major share of hereditary non-polymposis colorectal cancer families evaluable by linkage. Am J Hum Genet 1994: 55: 659-665.
17. Marra G, Boland CR. Hereditary nonpolyposis colorectal cancer: the syndrome, the genes, and historical perspectives. J Natl Cancer Inst 1995: 87: 1114-1125.
18. Fishel R, Kolodner R. Identification of mismatch repair genes and their role in the development of cancer. Curr Opin Genet Dev 1995: 5: 382-395.
19. Liu B, Parsons R, Papadopoulos N, Nicolaides NC, Lynch HT, Watson P, Jass JR, Dunlop M, Wyllie A, Peltomaki P, de la Chapelle A, Hamilton SR, Vogelstein B, Kinzler KW. Analysis of mismatch repair genes in hereditary non-polyposis colorectal cancer patients. Nat Med 1996: 2: 169-174.
20. Takahashi H, Behbakht K, McGovern PE, Chui H-C, Couch FJ, Weber BL, Friedman LS, King M-C, Furusato M, LiVolsi VA, Menzin AW, Lui PC, Benjamin I, Morgan MA, King SA, Rebane BA, Cardonick A, Mikuta JJ, Rubin SC, Boyd J. Mutation analysis of the BRCA1 gene in ovarian cancers. Cancer Res 1995: 55: 2998-3002.
21. Matsushima M, Kobayashi K, Emi M, Saito H, Saito J, Suzumori K, Nakamura Y. Mutation analysis of the BRCA1 gene in 76 Japanese ovarian cancer patients: four germline mutations, but no evidence of somatic mutation. Hum Mol Genet 1995: 4: 1953-1956.
22. Stratton JF, Gayther SA, Russell P, Dearden J, Gore M, Blake P, Easton D, Ponder BAJ. Contribution of BRCA1 mutations to ovarian cancer. N Engl J Med 1997: 336: 1125-1130.
23. Rubin SC, Blackwood MA, Bandera C, Behbakht K, Benjamin I, Rebbeck TR, Boyd J. BRCAI, BRCA2, and hereditary nonpolyposis colorectal cancer gene mutations in an unselected ovarian cancer population: relationship to family history and implications for genetic testing. Am J Obstet Gynecol 1998: 176: 670-677.
24. Takahashi H, Chui H-C, Bandera CA, Behbakht K, Lui PC, Couch FJ, Weber BL, LiVolsi VA, Furusato M, Rebane BA, Cardoniek A, Benjamin I, Morgan MA, King SA, Mikuta JJ, Rubin SC, Boyd J. Mutations of the BRCA2 gene in ovarian carcinomas. Cancer Res 1996: 56: 2738-2741.
25. Foster KA, Harrington P, Kerr J, Russell P, DiCioccio RA, Scott IV, Jacobs I, Chenevix-Trench G, Ponder BAJ, Gayther SA. Somatic and germline mutations of the BRCA2 gene in sporadic ovarian cancer. Cancer Res 1996: 56: 3622-3625.
26. Breast Cancer Information Core, 1998: http://www. nhgri.nih.gov/Intramural_research/Lab_transfer/Bic.
27. Levy-Lahad E, Catane R, Esienberg S, Kaufman B, Horneich G, Lishinsky E, Shohat M, Weber BL, Beller U, Lahad A, Halle D. Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families. Am J Hum Genet 1997: 60: 1059-1067.
28. Tonin PN, Mes-Masson A-M, Futreal PA, Morgan K, Mahon M, Foulkes WD, Cole DEC, Provencher D, Ghadirian P, Narod SA. Founder BRCA1 and BRCA2 mutations in French Canadian breast and ovarian cancer families. Am J Hum Genet 1998: 63: 1341-1351.
29. Godard B, Foulkes WD, Provencher D, Brunei S-B, Tonin PN, Mes-Masson A-M, Narod SA, Ghadirian P. Risk factors for familial and sporadic ovarian cancer among French Canadians: a case-control study. Am J Obstet Gynecol 1998: 179: 403-410.
30. Beller U, Halle D, Catane R, Kaufman B, Kornreich G, Levy-Lahad E. High frequency of BRCA1 and BRCA2 germline mutations in Ashkenazi Jewish ovarian cancer patients, regardless of family history. Gynecol Oncol 1997: 67: 123-126.
31. Schildkraut JM, Thompson WD. Familial ovarian cancer: a population-based case-control study. Am J Epidemiol 1988: 128: 456-466.
32. Greggi S, Genuardi M, Benedetti-Panici P, Cento R, Scambia G, Neri G, Mancuso S. Analysis of 138 consecutive ovarian cancer patients: incidence and characteristics of familial cases. Gynecol Oncol 1990: 39: 300-304.
33. Narod S, Tonin P, Lynch H, Watson P, Feunteun J, Lenoir G. Histology of BRCA1-associated ovarian tumours. Lancet 1994: 343: 236.
34. Amos CI Saw GL, Tucker MA, Hartge P. Age at onset for familial ovarian cancer. JAMA 1992: 268: 1896-1899.
35. Kerber RA, Slattery ML. The impact of family history on ovarian cancer risk. Arch Intern Med 1995: 155: 905-912.
36. Lynch HT, Watson P, Lynch JF, Conway RA, Fill M. Hereditary ovarian cancer: heterogeneity in age at onset. Cancer 1993: 71: 573-581.
37. Piver MS, Baker TR, Jishi MF, Sandecki AM, Tsukada Y, Natarajan N, Mettlin CJ, Blake CA. Familial ovarian cancer: a report of 658 families from the Gilda Radner Familial Ovarian Cancer Registry 1981-1991. Cancer 1993: 71: 582-588.
38. Rubin SC, Benjamin I, Behbakht K, Takahashi H, Morgan MA, LiVolsi VA, Berchuk A, Muto MG, Garber JE, Weber BL, Lynch HT, Boyd J. Clinical and pathological features of ovarian cancer in women with germline mutations of BRCA1. New Engl J Med 1996: 335: 1413-1416.
39. Oddoux C, Struewing JP, Clayton CM, Neuhausen S, Brody LC, Kaback M, Haas B, Norton L, Borgen P, Jhanwar S, Goldgar D, Ostrer H, Offit K. The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%. Nat Genet 1996: 14: 188-190.
40. Roa BB, Boyd AA, Volcik K, Richards CS. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nat Genet 1996: 14: 187-188.
41. Zweener RP, Verheijen RHM, Gille JJP, van Diest PJ, Pals G, Menko FH. Clinical and genetic evaluation of thirty ovarian cancer families. Am J Obstet Gynecol 1998: 178: 85-90.
42. Struewing JP, Abeliovich D, Peretz T, Avishai N, Kaback MM, Collins FS, Brody LC. The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals. Nat Genet 1995: 11: 198-200.